BridgeMD
Tests treatment safety and results for Subclinical hypothyroïdism
Official title Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
ClinicalTrials.gov ID: NCT07599241
What this study is testing
- What it's testing
- additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 to 75, women only
You may be able to join if
- subclinical hypothrodism (significant form)
- primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma)
- fatty liver (non alcholic type)
- elder females
You likely can't join if
- respiratory issues
- cardiac issues
- renal issues
The study team makes the final eligibility decision.
Where it's taking place
- Dokki, Giza Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dokki, Giza Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.